TY - JOUR T1 - Unified definition of relapse-free survival should be used for evaluating survival benefit in oesophageal adenocarcinoma JF - Gut JO - Gut DO - 10.1136/gutjnl-2020-321482 SP - gutjnl-2020-321482 AU - Weizheng Li Y1 - 2020/05/13 UR - http://gut.bmj.com/content/early/2020/05/13/gutjnl-2020-321482.abstract N2 - With great interest, I read the report1 by Turkington et al and applaud their proposed DNA damage immune response (DDIR) assay, which could predict survival benefit from DNA-damaging neoadjuvant chemotherapy following surgical resection in oesophageal adenocarcinoma (OAC). However, the definition of relapse-free survival (RFS) in their study was not widely accepted, leading to poor comparability among studies.In the present study, RFS was defined as … ER -